2,4-Di-tert-butyl-6-[1-(3,5-di-tert-butyl-2-hydroxy­phen­yl)eth­yl]phenyl 4-methyl­benzene­sulfonate

The title compound, C37H52O4S, was obtained by the reaction of 6,6′-(ethane-1,1-di­yl)bis­(2,4-di-tert-butyl­phenol) and 4-methyl­benzene-1-sulfonyl chloride. The mol­ecular conformation is stabilized by an intra­molecular O—H⋯O hydrogen bond. Two of the tert-butyl groups are disordered over two sets of sites with occupancies 0.530 (15)/0.470 (15) and 0.615 (11)/0.385 (11)

Correlated two-photon scattering in a one-dimensional waveguide coupled to two- or three-level giant atoms

We study the two-photon scattering processes in a one-dimensional waveguide coupled to a two- or three-level giant atom, respectively. The accumulated phase shift between the two coupling points can be utilized to alter the scattering processes. We obtain the exact interacting two-photon scattering wavefunction of these two systems following the Lippmann-Schwinger formalism, from which the analytical expressions of incoherent power spectra and second-order correlations are also derived. The incoherent spectrum, defined by the correlation of the bound state, serves as a useful indication of photon-photon correlation. The second-order correlation function gives a direct measure of photon-photon correlation. For photons scattered by the two-level giant atom, the accumulated phase shift can be used to improve photon-photon correlation,and adjust the evolution of the second-order correlation. In the system of the three-level giant atom, the photon-photon correlation can be substantially increased. Moreover, the photon-photon interactions and correlation distance of scattered photons can be further enhanced by tuning the accumulated phase shift

(E)-N-[2-(3,5-Di-tert-butyl-2-hydroxy­benzyl­ideneamino)cyclo­hexyl]-4-methyl­benzene­sulfonamide

In the crystal structure of the title compound, C28H40N2O3S, there are two mol­ecules per asymmetric unit; in each of these mol­ecules, the cyclo­hexyl rings adopt chair conformations. The dihedral angles between the benzene rings are 16.89 (9) and 34.11 (9)°. Each mol­ecule contains an intra­molecular O—H⋯N hydrogen bond, and inter­molecular N—H⋯O hydrogen bonds are also present. In both mol­ecules, the methyl groups of one tert-butyl group are disordered over two positions; the site-occupancy factors in both cases are ca 0.6 and 0.4

The Role of SPARC Protein Expression in the Progress of Gastric Cancer

We aimed to investigate the expression of SPARC (secreted protein, acidic and rich in cysteine) in gastric cancer and its relationship with tumor angiogenesis and cancer cells proliferation. Protein expression of SPARC, VEGF, CD34 and Ki-67 in 80 cases of gastric cancer and 30 cases of normal gastric tissue was evaluated by immunohistochemistry. CD34 staining was used as an indicator of microvessel density (MVD). Ki-67 labeling Index (LI) indicated cancer cells proliferation. Statistical analysis was used to investigate its relationship with clinical characteristics, tumor angiogenesis and cancer cells proliferation. SPARC expression was mainly in the stromal cells surrounding the gastric cancer cells, and was statistically significant differences between gastric cancer and normal gastric tissue (P < 0.05). Both the expression of SPARC and VEGF were related to differentiation degree, clinical stage, Lauren classification and lymph node metastasis (P < 0.05). Expression of SPARC was significantly negatively correlated with the expression of VEGF and MVD in gastric cancer tissues. Expression of SPARC was also negatively correlated with Ki-67-LI. Our findings suggest that both the expression of SPARC and VEGF are closed to tumor angiogenesis in gastric cancer, SPARC inhibited tumor angiogenesis but VEGF promoted tumor angiogenesis. SPARC also inhibited cells proliferation of gastric cancer

Association of body mass index in midlife with morbidity burden in older adulthood and longevity

Importance: Abundant evidence links obesity with adverse health consequences. However, controversies persist regarding whether overweight status compared with normal body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) is associated with longer survival and whether this occurs at the expense of greater long-term morbidity and health care expenditures. Objective: To examine the association of BMI in midlife with morbidity burden, longevity, and health care expenditures in adults 65 years and older. Design, Setting, and Participants: Prospective cohort study at the Chicago Heart Association Detection Project in Industry, with baseline in-person examination between November 1967 and January 1973 linked with Medicare follow-up between January 1985 and December 2015. Participants included 29 621 adults who were at least age 65 years in follow-up and enrolled in Medicare. Data were analyzed from January 2020 to December 2021. Exposures: Standard BMI categories. Main Outcomes and Measures: (1) Morbidity burden at 65 years and older assessed with the Gagne combined comorbidity score (ranging from -2 to 26, with higher score associated with higher mortality), which is a well-validated index based on International Classification of Diseases, Ninth Revision codes for use in administrative data sets; (2) longevity (age at death); and (3) health care costs based on Medicare linkage in older adulthood (aged ≥65 years). Results: Among 29 621 participants, mean (SD) age was 40 (12) years, 57.1% were men, and 9.1% were Black; 46.0% had normal BMI, 39.6% were overweight, and 11.9% had classes I and II obesity at baseline. Higher cumulative morbidity burden in older adulthood was observed among those who were overweight (7.22 morbidity-years) and those with classes I and II obesity (9.80) compared with those with a normal BMI (6.10) in midlife (P \u3c .001). Mean age at death was similar between those who were overweight (82.1 years [95% CI, 81.9-82.2 years]) and those who had normal BMI (82.3 years [95% CI, 82.1-82.5 years]) but shorter in those who with classes I and II obesity (80.8 years [95% CI, 80.5-81.1 years]). The proportion (SE) of life-years lived in older adulthood with Gagne score of at least 1 was 0.38% (0.00%) in those with a normal BMI, 0.41% (0.00%) in those with overweight, and 0.43% (0.01%) in those with classes I and II obesity. Cumulative median per-person health care costs in older adulthood were significantly higher among overweight participants ($12 390 [95$10 427 to $14 354]) and those with classes I and II obesity ($23 396 [95% CI, $18 474 to$28 319]) participants compared with those with a normal BMI (P \u3c .001). Conclusions and Relevance: In this cohort study, overweight in midlife, compared with normal BMI, was associated with higher cumulative burden of morbidity and greater proportion of life lived with morbidity in the context of similar longevity. These findings translated to higher total health care expenditures in older adulthood for those who were overweight in midlife